Ikarian Capital, LLC Apellis Pharmaceuticals, Inc. Call Options Transaction History

Ikarian Capital, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $4.33 Million - $6.17 Million	150,000 New	150,000 $4.33 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $5.48 Million - $9.57 Million	147,635 Added 6242.49%	150,000 $8.98 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $55,932 - $211,005	2,365 New	2,365 $89,000
Q2 2022 Aug 12, 2022	SELL	$35.07 - $59.21 $1.82 Million - $3.07 Million	-51,900 Reduced 29.64%	123,200 $5.57 Million
Q1 2022 May 13, 2022	SELL	$35.46 - $54.12 $882,954 - $1.35 Million	-24,900 Reduced 12.45%	175,100 $8.9 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $1.01 Million - $1.62 Million	-33,000 Reduced 14.16%	200,000 $9.46 Million
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $2.1 Million - $4.68 Million	-67,000 Reduced 22.33%	233,000 $7.68 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $2.44 Million - $3.87 Million	59,700 Added 24.84%	300,000 $19 Million
Q4 2019 Jan 31, 2020	BUY	$22.1 - $30.8 $5.31 Million - $7.4 Million	240,300 New	240,300 $7.36 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.